Recently added

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Cho, Byoung Chul; Gutiérrez, Vanesa Lores; alip, adlinda; Lu, Shun; Besse, Benjamin; FELIP, ENRIQUETA (Elsevier, 2024-09)

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Bas, Raphaëlle; Kim, Heejeong; Di Meglio, Antonio; Bernstein Molho, Rinat; Arecco, Luca; Bruzzone, Marco; Carrasco Lopez, Estela (Elsevier, 2024-09)

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Juan-Vidal, Oscar; Mountzios, Giannis; Reinmuth, Niels; de Marinis, Filippo; Paz-Ares, Luis; FELIP, ENRIQUETA (American Society of Clinical Oncology, 2024-08-20)

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

chida, keigo; Xu, Rui-Hua; Passhak, Maria; Teng, Hao-Wei; Shergill, Ardaman; García-Alfonso, Pilar (American Society of Clinical Oncology, 2024-08-20)

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Bancroft, Elizabeth; Page-Gould, Elizabeth; Brook, Mark; Pope, Jennifer; Thomas, Sarah; Myhill, Kathryn Jane; Perez Ballestero, Eduard; Cruellas , Mara (Wiley, 2024-09)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA ﻿

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers ﻿

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study ﻿

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study ﻿

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers ﻿

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers